PAI Pharma acquires Nexus, adding 20+ hospital injectable products

Image
PAI Pharma acquires Nexus, adding 20+ hospital injectable products

PARSIPPANY, N.J. – November 12, 2026 -- PAI Pharma, a portfolio company of Olympus Partners, has acquired Nexus Pharmaceuticals, LLC, adding more than 20 hospital injectable products to its sterile injectable portfolio. The company announced the deal on November 12, 2026 and did not disclose the purchase price.

Nexus is the second sterile injectable acquisition PAI cites in the announcement. It follows the company's recent purchase of Nivagen, which brought aseptic manufacturing capabilities in Sacramento, California. PAI describes itself as a developer and manufacturer of oral liquid medicines and Ready-To-Use sterile injectable and hospital-focused products.

The two targets differ in how they produce. The announcement describes Nexus as combining development and analytical expertise with a network of contract manufacturing partners. Nivagen's Sacramento site gives PAI aseptic capability of its own. The announcement does not say whether any Nexus products will move to Sacramento.

Nexus products are used in critical care, oncology and other hospital settings. According to Nexus's own description, its portfolio includes therapies that have historically faced supply shortages. Hospital buyers of those products now deal with a counterparty owned by PAI. The company says the deal lets it serve hospitals and healthcare providers with a broader range of products.

William Blair was exclusive advisor to PAI, and Kirkland & Ellis LLP was PAI's legal counsel. Proskauer Rose LLP advised Nexus.

Published by:
fairsonline_team
News Type